Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial).
Key facts
- Who runs it
- Ole Hyldegaard
- Where
- Belgium and Norway2 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 1,480 people, planned
- Started
- 4 Apr 2026
- Expected to end
- 30 Jun 2033
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Hyperbaric oxygen treatment
- Standard of Care (Investigator Choice)
- Record updated
- 4 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Adults (age ≥18 years)
- Surgical confirmed NSTI (defined by perioperative tissue characteristics observed by the surgeon. The diagnosis is based on sign as necrotic or deliquescent soft tissue with widespread undermining of the surrounding tissue)
Who cannot take part
- Previously randomized into the HOT-NSTI trial
- Allergy against study drug
- Contraindications for HBO2 treatment according to local protocol (e.g., undrained pneumothorax)
- Confirmed pregnancy
- Referred to palliative care
- Known objection by the patient to participate in the trial
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Necrotizing soft-tissue infection (NSTI) is a rare, severe, fast-progressing bacterial infection within the soft tissue compartment. The NSTI mortality rate remain high and largely unaltered in the last decades. The standard of care in NSTI is multidisciplinary and includes surgery, intensive care, and broad-spectrum antibiotics. Hyperbaric oxygen (HBO2) treatment is an adjunctive treatment potentially improving survival, but is not standard of care in many centres, presumably as no evidence of its benefit from randomized clinical trial exists.
Read full original descriptionShow less
The primary objective of this trial, HOT-NSTI, is to investigate the effect of adjunctive HBO2 treatment on 30-day all-cause mortality in patients with NSTI.
The 2 groups in the trial
- Standard of careExisting treatment, for comparison
standard of care (e.g. intensive care, surgery, antibiotics)
Treatment: Standard of Care (Investigator Choice)
- Standard of care + hyperbaric oxygen treatmentTreatment being tested
standard of care (e.g. intensive care, surgery, antibiotics) + hyperbaric oxygen treatment
Treatment: Hyperbaric oxygen treatment and Standard of Care (Investigator Choice)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial)
- Record updated
- 4 September 2026